With OBJ done for the year, Higgins could be the man to step up for Cleveland.
With OBJ done for the year, Higgins could be the man to step up for Cleveland.
Four Royal Household Cavalrymen died in the July 1982 blast.
The legal challenge has been brought against the Tavistock and Portman NHS Trust.
Japanese shares rose toward a 29-year high on Tuesday, tracking gains in U.S. stock futures on the back of growing optimism that major drugmakers will roll out coronavirus vaccines some time before the end of the year. The Nikkei 225 index climbed 1.42% to 26,810.05 by 0212 GMT, moving closer toward a 29-year high of 26,830.10 reached on Monday. The broader Topix rose 0.86% to 1,769.91.
POLITIQUE. En accord avec la famille de feu Marc-André Bédard, le premier ministre du Québec, François Legault, a annoncé qu’une cérémonie d’hommage national sera organisée pour honorer la mémoire de ce grand homme de la politique québécoise, à une date ultérieure, lorsque la situation sanitaire le permettra. «Marc-André Bédard, c’était un amoureux du Québec, un amoureux de son peuple. C’était un homme d’une immense gentillesse. Je suis attristé de le perdre et je veux présenter, au nom du gouvernement du Québec, mes plus sincères condoléances à ses fils, à ses proches et à toute la population du Saguenay–Lac-Saint-Jean. Mes pensées sont avec vous», souligne François Legault, premier ministre du Québec. Le drapeau du Québec sera également mis en berne, ce jour-là, sur la tour centrale de l’hôtel du Parlement et sur l’édifice du ministère de la Justice. Un registre de condoléances sera par ailleurs mis en ligne. Le premier ministre invite tous les Québécois à exprimer leurs condoléances et leurs messages de sympathie à la famille et aux proches. Rappelons que Marc-André Bédard, ancien vice-premier ministre du Québec et ministre de la Justice sous le gouvernement de René Lévesque, s’est éteint le 25 novembre 2020 à l’âge de 85 ans. Instigateur de la réforme du Code civil du Québec, de la modernisation du droit de la famille ainsi que de la modification de la Charte des droits et libertés de la personne pour interdire la discrimination fondée sur l’orientation sexuelle, il a marqué profondément l’histoire de la politique québécoise. L’avocat de formation a également encadré la création du Conseil de la magistrature. Stéphane Lévesque, Initiative de journalisme local, L'Hebdo Journal
"We've got plenty of time" to overturn the election, said Donald Trump's daughter-in-law.
HONOLULU — A U.S. judge sentenced a former high-ranking Honolulu prosecutor to 13 years in prison Monday and her retired police chief husband to seven years, saying she stole money from her own grandmother and then used his law enforcement power to frame her uncle for a crime he didn’t commit -- all to maintain the couple’s lavish lifestyle. Katherine and Louis Kealoha, now estranged, were once a respected power couple. Louis Kealoha agreed to retire amid a wide-ranging federal investigation. She later gave up her law license. “This case has staggered the community in many ways,” U.S. District Judge J. Michael Seabright said. He described how Katherine Kealoha orchestrated a reverse mortgage scheme that forced her grandmother to sell her home, framed her uncle for stealing the Kealohas' home mailbox, stole money from children whose trusts she controlled as a lawyer, cheated her uncle out of his life savings, convinced her firefighter lover to lie about their affair and used her position as a prosecutor to turn a drug investigation away from her doctor brother. “Truth can be stranger than fiction,” the judge said at Katherine Kealoha's sentencing. Later, he told Louis Kealoha that while his wife was the mastermind, “you did master the frame job that followed," and the scheme couldn't have succeeded without the Honolulu Police Department. A jury convicted the Kealohas last year of conspiracy, along with two former officers who are scheduled to be sentenced Tuesday. The case is especially shocking, Seabright said, because of the role a police chief of a “major American city,” played. “Think about that, the chief of police of one of the largest police departments in the country ... swears to tell the truth, the whole truth and nothing but the truth,” and lies, the judge said of Louis Kealoha's false testimony at the trial of his wife's uncle for stealing the couple's mailbox. The trial ended in a mistrial that prosecutors say the then-chief caused on purpose to thwart the investigation. The Kealohas later pleaded guilty to bank fraud, saying they provided false information to obtain loans. They went to great lengths to maintain a lifestyle they couldn't afford on public servant salaries, the judge said. Katherine Kealoha, 51, also pleaded guilty to an identity theft charge, saying she got an officer to forge a police report she used to explain negative information on a credit report. She also pleaded guilty to a charge that involved protecting her brother from the drug investigation. In a letter to the judge, she blamed a prescription drug addiction for clouding her judgment. “My client was on drugs, her mind was not clear and she did a lot of bad things,” her lawyer, Gary Singh, said in court. Kealoha apologized to her family in court and asked for forgiveness. “To my uncle, especially,” she said. “I know that he has been through so much pain and so much hurt.” Kealoha's aunt, Charlotte Puana Malott, read a letter she said her 100-year-old mother, Florence Puana, wrote before she died in February about her granddaughter's “ruthless scheme." “I was 90 years old in 2009 when I agreed to a reverse mortgage on my home, not really understanding what it meant. It seemed complicated, yet I trusted you, Katherine,” the letter said. Kealoha came to Puana and her son Gerard Puana with an idea about taking out a reverse mortgage on her grandmother’s home to help buy a condo her uncle wanted. Kealoha said she would consolidate her debts and promised her uncle and grandmother that she would pay off the loan. She used the money to buy her uncle’s condo, but instead of paying off the loan, she spent the leftover money on luxuries, including $26,000 for an induction banquet when her husband became police chief and $10,000 on Mercedes-Benz and Maserati car payments, the judge said. “She perverted justice. And she did so for her own personal reasons,” said Michael Wheat, a special federal prosecutor. “To facilitate a lifestyle and a facade and an image in this community.” Framing her uncle for stealing the Kealohas' mailbox was to make him less credible in the family financial dispute, the judge said. “We still don't know sitting here today, who stole the mailbox,” Seabright said, adding that it clearly wasn't Gerard Puana. He told Katherine Kealoha that she used the police “to do your dirty work.” Louis Kealoha, 60, filed for divorce after they were convicted. He said at his sentencing that he's deeply sorry, ashamed and failed to live up to the standards of a police chief. “This is the last place in my life I thought I’d be and I vow never to be here again," he said. Partly because of the COVID-19 pandemic, Seabright agreed to allow Kealoha to remain free on bond until he self-surrenders in April. His wife has been in the Honolulu Federal Detention Center since they were convicted. Monday's sentencings come after several postponements. Concern about the spread of the coronavirus caused a delay in March, then a Nov. 3 date was changed after officials realized it was Election Day. “COVID has kept us from this date for quite a while,” the judge said. Jennifer Sinco Kelleher, The Associated Press
Dans l’énoncé économique qu’elle a déposé à la Chambre des communes, la ministre des Finances, Chrystia Freeland, annonce un déficit d’au moins 381,6 milliards de dollars, soit 38,4 milliards de plus que les prévisions annoncées en juillet 2019. Ottawa envisage une dette fédérale à hauteur de 1107,4 milliards de dollars équivalents à plus de 50 % du produit intérieur brut du Canada. « Il est plus risqué de fournir trop peu d’aide que d’en fournir trop. Dans le présent Énoncé économique de l’automne, nous faisons preuve de transparence quant à l’incertitude qui persiste » a indiqué la ministre Freeland, prévoyant que de nouvelles restrictions liées à la pandémie de Covid-19 pourraient faire retomber le solde budgétaire. La ministre a précisé que le Canada allait connaître un manque à gagner d’environ 136,7 milliards de dollars pour l’exercice financier 2021-2022, et 59,7 milliards durant l’exercice suivant. Selon les prévisions du gouvernement pour les cinq prochaines années, le retour à l’équilibre budgétaire est envisagé autour de 2024 avec un déficit inférieur à celui de 2019. « La crise actuelle est le plus grand défi que notre pays ait eu à relever depuis la Seconde Guerre mondiale. C’est le choc économique le plus grave que nous avons connu depuis la Grande Dépression, et la crise de santé publique la plus grave que nous ayons connue depuis la grippe espagnole, il y a cent ans. Il est important que les Canadiens sachent que le gouvernement fédéral sera là pour les aider à traverser cette crise, quoi qu’il arrive », a affirmé la ministre Freeland dans son allocution à la Chambre des communes. Un communiqué du ministère des Finances prévoit que « lorsque le virus sera maîtrisé, le gouvernement du Canada investira dans un plan de croissance représentant environ 3 % à 4 % du produit intérieur brut (PIB), soit entre jusqu’à 70 milliards et 100 milliards de dollars, sur trois ans afin de relancer l’économie. » Godlove Kamwa, Initiative de journalisme local, Le Canada Français
Democrat Christy Smith conceded Monday in a knife-edged loss to Republican rival Mike Garcia, who retained his Congressional seat in the 25th District north of Los Angeles. “With final votes counted in this race, it’s clear we will not be able to close the 339-vote gap," Smith said in a statement. Garcia had claimed victory last week but Smith had said that assertion was premature because not all of the more than 338,000 votes cast had been counted.
The Wireless Gas Detection Market will grow by $ 524.65 mn during 2020-2024
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Progenity also expects to grant the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $15 million principal amount of notes. The notes will be senior, unsecured obligations of Progenity, will accrue interest payable semi-annually in arrears and will mature on December 1, 2025, unless earlier repurchased, redeemed or converted. At any time from and including the date that is 30 calendar days after the initial closing date of the offering and before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their notes at their option into shares of Progenity’s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. In addition, noteholders that convert their notes before December 1, 2022 will, in certain circumstances, be entitled to an additional cash payment upon conversion. The notes will be redeemable, in whole and not in part, for cash at Progenity’s option at any time on or after December 1, 2023, but only if the last reported sale price per share of Progenity’s common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.Progenity intends to use the net proceeds from the offering, together with the net proceeds from the underwritten public offering of common stock referred to below, to support its operations, to invest in its molecular testing research and development program, to invest in research and development with respect to its precision medicine platform, and for working capital and general corporate purposes.Certain entities affiliated with Athyrium Capital Management, LP (“Athyrium”), one of Progenity’s affiliates, have indicated their intent to acquire up to $103.5 million in aggregate principal amount of notes, consisting of up to $25 million principal amount of affiliate notes to be purchased for cash in the offering and, pursuant to a separate exchange agreement, up to an additional $78.5 million principal amount of affiliate notes to be issued in exchange for the discharge of amounts outstanding under Progenity’s credit and security agreement with a fund managed by Athyrium.In a separate press release, Progenity also announced today its intention to offer, in a separate, underwritten public offering, subject to market and other conditions, $25 million of shares of its common stock, plus up to an additional $3.75 million of shares of its common stock that the underwriters of the common stock offering have the option to purchase from Progenity. The completion of the offering of the notes is not contingent on the completion of the offering of common stock, and the completion of the offering of common stock is not contingent on the completion of offering of the notes. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any common stock in the public offering.The offer and sale of the notes and the shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or the shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.About ProgenityProgenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.Forward-Looking StatementsThis press release includes forward-looking statements, including statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offerings and the intended use of the proceeds. Forward-looking statements represent Progenity’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including market interest rates, the trading price and volatility of Progenity’s common stock and risks relating to Progenity’s business, including those described in periodic reports that Progenity files from time to time with the SEC. Progenity may not consummate the proposed offerings described in this press release and, if the proposed offerings are consummated, cannot provide any assurances regarding the final terms of the offer or the notes or its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Progenity does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.Contact InformationInvestor Contact: Robert Uhl Managing Director, Westwicke ICR firstname.lastname@example.org (619) 228-5886Media Contact: Kate Blom-Lowery CG Life email@example.com (858) 457-2436
Isai Morocho died unexpectedly during Thanksgiving break, according to his school
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has commenced an underwritten public offering of $25 million of shares of its common stock. In addition, Progenity is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $3.75 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. In a separate press release, Progenity also announced today its intention to offer, in a separate, private offering to qualified institutional buyers, subject to market and other conditions, $75 million aggregate principal amount of convertible senior notes due 2025 (the “notes”), plus up to an additional $15 million aggregate principal amount of notes that the initial purchaser of the notes has the option to purchase from Progenity. The completion of the offering of common stock is not contingent on the completion of the offering of the notes, and the completion of the offering of notes is not contingent on the completion of offering of common stock. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any notes or any shares of common stock issuable upon conversion of the notes.Piper Sandler & Co. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering of common stock. BTIG, LLC is acting as the lead manager for the offering of common stock.A registration statement relating to the offering of common stock has been filed with the Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This offering is being made only by means of a prospectus, copies of which may be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by email at firstname.lastname@example.org; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email a request to email@example.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About ProgenityProgenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.Forward Looking StatementsThis press release contains “forward-looking statements,” which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including, but not limited to, Progenity’s expectations regarding the proposed offerings are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause Progenity’s actual results to differ materially from the forward-looking statements expressed or implied in this press release, the uncertainties related to market conditions and the completion of the offerings on the anticipated terms or at all, the uncertainties inherent in the clinical drug development process, such as the regulatory approval process, the timing of regulatory filings, and other matters, including the ongoing COVID-19 pandemic and associated shelter-in-place orders, that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of Progenity’s products, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Progenity’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 11, 2020, and other subsequent documents filed with the SEC. Progenity claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Progenity expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.Investor Contact: Robert Uhl Managing Director, Westwicke ICR firstname.lastname@example.org (619) 228-5886Media Contact: Kate Blom-Lowery CG Life email@example.com (619-743-6294)
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sio Gene Therapies, Inc. (“Sio” or the “Company”) (NASDAQ: AXGT). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980. The investigation concerns whether Sio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On October 29, 2020, Sio disclosed that manufacturing delays would potentially postpone the start of enrollment in the Company’s planned randomized, sham-controlled trial of AXO-Lenti-PD gene therapy for Parkinson’s disease, and that the trial seemed unlikely to enroll patients by the end of the calendar year 2021.On this news, Sio’s stock price fell $1.52 per share, or 41.64%, to close at $2.13 per share on October 30, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT: Robert S. Willoughby Pomerantz LLP email@example.com 888-476-6529 ext. 7980
A systems error led Australia's biggest bank to overcharge interest on business overdraft accounts to a total of more than A$2.9 million ($2.13 million) between 2011 and 2018, the Australian Securities & Investments Commission (ASIC) said. CBA "provided customers with terms and conditions for certain credit facilities that stated an interest rate to be charged or that had been charged," the regulator said in its statement, adding this was 16% a year in most cases.
En marge de son plan de relance post-Covid-19, la ministre des Finances Chrystia Freeland annonce des dépenses en faveur des ménages dès la période des fêtes. Le taux maximal de la subvention salariale d’urgence offerte aux employeurs passe de 65 % à 75 % de décembre 2020 à mars 2021. Dans l’énoncé économique présenté par Mme Freeland, les prestations d’urgence seront revues à la hausse avec des versements supplémentaires aux familles ayant des enfants de moins de 6 ans. Il est prévu que les ménages ayant un revenu annuel de moins de 120 000 dollars recevront 1200 dollars par enfant et la moitié pour ceux dont les revenus vont au-delà de ce seuil annuel. « Ces mesures apportent une certitude économique aux Canadiens en cette période de turbulence et d’incertitude. Elles nous aideront à passer à travers les mois d’hiver », a annoncé la vice-première ministre. Ottawa prévoit un investissement supplémentaire de 274,2 millions de dollars dans la formation pour aider les couches les plus affectées par la pandémie de Covid-19. Le plan de relance fait allusion aux Autochtones, aux personnes handicapées, aux femmes et aux immigrants. Un ambitieux programme de relance projette de générer jusqu’à un million d’emplois pendant les quatre prochaines années en vue de retrouver la stabilité économique. La mise en œuvre de cette relance d’un coût de 70 à 100 millions de dollars sur 3 ans, pourrait commencer au troisième trimestre de l’année 2021 selon les projections du fédéral. L’énoncé économique présenté à la Chambre des communes prévoit également une subvention pouvant atteindre 5000 dollars à compter du 1er décembre pour rendre les habitations plus écoénergétiques. Près de 700 000 subventions d’une enveloppe de 2,6 milliards de dollars seront distribuées aux Canadiens pour les inciter à procéder aux rénovations nécessaires. Quant aux entreprises, elles auront une rallonge de 14,8 milliards de dollars à travers l’augmentation des subventions salariales d’urgence à 75 % jusqu’en mars. La subvention d’urgence pour le loyer est également prolongée jusqu’à mars 2021. Un nouveau programme de crédit octroyant des prêts à faibles taux d’intérêt est consacré aux secteurs les plus vulnérables comme le tourisme, l’hébergement et le domaine des arts et du spectacle. Enfin, Ottawa n’envisage qu’une augmentation des transferts canadiens en matière de santé de l’ordre de 3 % par an. Les dirigeants des provinces et territoires avaient fait front commun pour réclamer une rallonge de 28 milliards de dollars, soit une hausse de 22 % à 35 %. Godlove Kamwa, Initiative de journalisme local, Le Canada Français
With the Chargers' record at 3-8 and coaching appearing suspect during games, Anthony Lynn's head coaching job is very much in jeopardy.
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Credit Acceptance To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 30, 2020) - If you suffered losses exceeding $100,000 investing in Credit Acceptance stock or options between November 1, 2019 and August 28, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/CACC or call Faruqi & Faruqi partner James Wilson directly ...
Sites that let you buy gifts from the best of small businesses, from Halifax to Toronto to Edmonton to Whitehorse.
The five Olympic rings are back in Tokyo Bay. The rings arrived on Tuesday after a short cruise from nearby Yokohama and are positioned on a barge in the shadow on Tokyo's Rainbow Bridge. The rings will be lighted at night and herald the coming of the Tokyo Olympics, which are to open on July 23, 2021, followed by the Paralympics on Aug. 24.
J.D. Heyman has been terminated as the editor in chief of Entertainment Weekly “effective immediately,” a spokesperson for parent company Meredith told TheWrap on Monday.No reason was given for the ouster of the veteran editor, formerly at People magazine and the top editor at EW since June 2019.“JD Heyman and Entertainment Weekly (EW), produced by Meredith Corporation, have parted ways, effective immediately,” the spokesperson said. “Meredith thanks JD for his contributions to the EW and People brands over his many years of service. A national search is being conducted to fill the role.”Until that time, Meredith said Alex Brez, EW’s director of editorial operations for entertainment and style and Tim Leong, EW’s deputy editor and creative director, will oversee editorial operations for the magazine.Heyman, the former deputy editor at People magazine, was appointed the editor in chief of EW last year as the publication scaled back to a monthly print product and shifted its focus to digital offerings.Meredith took over EW as part of its $2.8 billion purchase of Time Inc., which started the publication in 1990.Heyman did not immediately respond to TheWrap’s request for comment.Read original story Entertainment Weekly’s JD Heyman Is Out as Editor in Chief ‘Effective Immediately’ At TheWrap